Twist Bioscience Launches Complex Gene Synthesis Service
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 04 2026
0mins
Source: Newsfilter
Twist Bioscience's stock rose by 5.06% as it crossed above the 5-day SMA, reflecting positive market conditions.
The company launched a complex gene synthesis service that can accept 99.5% of clonal gene sequences, significantly enhancing customer satisfaction in nucleic acid therapeutics and AI-driven drug discovery. This innovation positions Twist as a reliable partner for scientists, addressing urgent market needs for high-complexity sequences. The launch is expected to drive further growth in the company's revenue and market share.
This new service not only showcases Twist's technological advancements but also aligns with the growing demand in the biotechnology sector, potentially leading to increased customer engagement and revenue growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TWST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TWST
Wall Street analysts forecast TWST stock price to fall
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 91.030
Low
39.00
Averages
41.25
High
43.00
Current: 91.030
Low
39.00
Averages
41.25
High
43.00
About TWST
Twist Bioscience Corporation provides customizable solutions across the biological continuum that enable scientific discovery and development across therapeutics, diagnostics, and other high-growth markets. The Company's proprietary silicon-based platform delivers precision, scale, and speed, supporting consistent, high-quality performance across a range of applications. The Company’s platform is a differentiated method of manufacturing synthetic deoxyribonucleic acid (DNA) by writing DNA on a silicon chip. By integrating proprietary hardware, software, and scalable infrastructure, including its e-commerce platform. The Company has extended this platform beyond DNA synthesis to offer an integrated portfolio that includes synthetic genes, next-generation sequencing, applications, sample preparation tools, antibody libraries, and biologic discovery services. Leveraging the same platform, it also manufactures synthetic ribonucleic acid (RNA) and expresses antibody proteins.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of XBI ETF's 52-Week Price Fluctuations
- Price Range Analysis: The XBI ETF has a 52-week low of $83.02 and a high of $160.82, with the latest trade at $159.31, indicating strong performance near its peak and reflecting ongoing market interest in the biotechnology sector.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides investors with deeper insights for technical analysis, aiding in the assessment of market trends and potential buy or sell opportunities to optimize investment decisions.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors are buying and selling “units” that can be created or destroyed based on investor demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs highlights significant inflows (new units created) or outflows (old units destroyed), which directly affects the underlying holdings of the ETF and consequently impacts the market performance of related stocks.
See More
Investors Must Maintain Emotional Neutrality
- Investor Mindset: Robert Kiyosaki emphasizes that successful business owners and investors must maintain emotional neutrality towards winning and losing, viewing these as mere parts of the game, which helps in staying rational and patient in volatile markets.
- Twist Bioscience Performance: Twist Bioscience reported strong revenue performance for fiscal year 2025 and the first half of fiscal 2026, with third-quarter revenue expected to reach approximately $114 million to $115 million, reflecting a year-over-year growth of about 19%, showcasing its sustained growth potential in synthetic biology.
- Biodesix Clinical Validation: Biodesix's Nodify CDT test demonstrated strong performance in the largest clinical validation study for lung nodule biomarkers, with financial results for Q2 2026 expected to further boost stock prices, highlighting its leading position in early lung cancer diagnosis.
- Mirum Pharmaceuticals Progress: Mirum Pharmaceuticals' strong Q1 2026 results and the anticipated FDA decision on Zilurgisertib indicate its innovative capabilities in rare disease treatments and market confidence, which are expected to drive future stock performance.
See More
Analysis of XBI ETF Trading Dynamics
- 52-Week Price Range: The XBI ETF has a 52-week low of $82.04 and a high of $150.49, with the latest trade at $149.87, indicating strong investor interest and volatility near its peak, reflecting ongoing confidence in the biotech sector.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average allows investors to better assess XBI's price trends, enabling more precise investment strategies and enhancing the effectiveness of trading decisions.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units', providing flexibility that allows ETFs to better accommodate market demand, thus increasing their attractiveness as investment vehicles.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify significant inflows or outflows; inflows necessitate purchasing underlying assets, while outflows may lead to selling, impacting the performance of individual stocks within the ETF.
See More
Eli Lilly and Twist Leverage AI to Accelerate Drug Development
- AI Innovation at Eli Lilly: Eli Lilly is collaborating with OpenAI to accelerate drug discovery and has established an AI co-innovation lab with Nvidia, aiming to identify promising molecules faster than traditional methods, which is expected to enhance its competitive edge in drug development.
- Strong Financial Performance: In Q1 2026, Eli Lilly reported a 56% revenue increase to $19.8 billion and a 168% surge in net income to $7.4 billion, demonstrating the company's ability to achieve high growth efficiency despite its large scale, further solidifying its market position.
- Growth Potential for Twist: Twist Bioscience's revenue rose 19% to $110.7 million in Q2 of fiscal 2026, marking 13 consecutive quarters of growth; however, its net loss widened to $44 million, yet the partnership with Amazon provides significant momentum for future drug development.
- Market Outlook Analysis: Both companies showcase distinct approaches in AI-driven drug development, with Eli Lilly focusing on innovation in established drugs while Twist seeks higher-risk returns in synthetic DNA, reflecting the broad potential of AI in the pharmaceutical industry.
See More
Eli Lilly and Twist Bioscience: AI in Drug Development
- AI Innovation at Eli Lilly: Eli Lilly collaborates with OpenAI for drug discovery and establishes an AI co-innovation lab with Nvidia, aiming to accelerate drug development and enhance its position in the competitive pharmaceutical market.
- Strong Financial Performance: In Q1 2026, Eli Lilly reported a 56% revenue increase to $19.8 billion and a 168% surge in net income to $7.4 billion, indicating improved operational efficiency and promising future growth potential despite its large scale.
- Market Dynamics for Twist Bioscience: Twist Bioscience's revenue rose 19% to $110.7 million in Q2 2026, marking 13 consecutive quarters of growth, although net losses widened to $44 million, highlighting challenges faced during expansion.
- Partnership with Amazon: Twist Bioscience has become a key lab in Amazon's Bio Discovery platform, leveraging AI to design drugs and collaborate with real-world partners, which is expected to create new business growth opportunities and enhance its market competitiveness.
See More
Eli Lilly and Twist Bioscience's AI Drug Development Strategies
- AI Innovation at Eli Lilly: Eli Lilly collaborates with OpenAI for drug discovery and establishes an AI co-innovation lab with Nvidia to accelerate the identification of promising drug molecules, resulting in a 56% revenue increase to $19.8 billion and a 168% rise in net income to $7.4 billion in Q1 2026, indicating significant efficiency improvements.
- New Drug Potential: Lilly's newly approved weight-loss pill, Foundayo, which can be taken at any time, replaces injections and is expected to attract a broader patient base, further expanding market share and enhancing the company's position in the rapidly growing weight-loss drug market.
- Twist's Growth Risks: Twist Bioscience's stock has risen over 136% in the past year, despite a 26% decline over the past five years, with Q2 2026 revenue up 19% to $110.7 million, marking 13 consecutive quarters of revenue growth, although net loss widened to $44 million primarily due to a $7.2 million settlement.
- Partnership with Amazon: Twist's collaboration with Amazon positions it as a key lab in the Amazon Bio Discovery platform, leveraging AI to design drugs and develop them with real-world partners, highlighting the company's critical role in AI-driven drug development despite facing higher uncertainty.
See More
Analysis of XBI ETF's 52-Week Price Fluctuations
- Price Range Analysis: The XBI ETF has a 52-week low of $83.02 and a high of $160.82, with the latest trade at $159.31, indicating strong performance near its peak and reflecting ongoing market interest in the biotechnology sector.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides investors with deeper insights for technical analysis, aiding in the assessment of market trends and potential buy or sell opportunities to optimize investment decisions.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors are buying and selling “units” that can be created or destroyed based on investor demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs highlights significant inflows (new units created) or outflows (old units destroyed), which directly affects the underlying holdings of the ETF and consequently impacts the market performance of related stocks.
See More
Investors Must Maintain Emotional Neutrality
- Investor Mindset: Robert Kiyosaki emphasizes that successful business owners and investors must maintain emotional neutrality towards winning and losing, viewing these as mere parts of the game, which helps in staying rational and patient in volatile markets.
- Twist Bioscience Performance: Twist Bioscience reported strong revenue performance for fiscal year 2025 and the first half of fiscal 2026, with third-quarter revenue expected to reach approximately $114 million to $115 million, reflecting a year-over-year growth of about 19%, showcasing its sustained growth potential in synthetic biology.
- Biodesix Clinical Validation: Biodesix's Nodify CDT test demonstrated strong performance in the largest clinical validation study for lung nodule biomarkers, with financial results for Q2 2026 expected to further boost stock prices, highlighting its leading position in early lung cancer diagnosis.
- Mirum Pharmaceuticals Progress: Mirum Pharmaceuticals' strong Q1 2026 results and the anticipated FDA decision on Zilurgisertib indicate its innovative capabilities in rare disease treatments and market confidence, which are expected to drive future stock performance.
See More
Analysis of XBI ETF Trading Dynamics
- 52-Week Price Range: The XBI ETF has a 52-week low of $82.04 and a high of $150.49, with the latest trade at $149.87, indicating strong investor interest and volatility near its peak, reflecting ongoing confidence in the biotech sector.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average allows investors to better assess XBI's price trends, enabling more precise investment strategies and enhancing the effectiveness of trading decisions.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units', providing flexibility that allows ETFs to better accommodate market demand, thus increasing their attractiveness as investment vehicles.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify significant inflows or outflows; inflows necessitate purchasing underlying assets, while outflows may lead to selling, impacting the performance of individual stocks within the ETF.
See More
Eli Lilly and Twist Leverage AI to Accelerate Drug Development
- AI Innovation at Eli Lilly: Eli Lilly is collaborating with OpenAI to accelerate drug discovery and has established an AI co-innovation lab with Nvidia, aiming to identify promising molecules faster than traditional methods, which is expected to enhance its competitive edge in drug development.
- Strong Financial Performance: In Q1 2026, Eli Lilly reported a 56% revenue increase to $19.8 billion and a 168% surge in net income to $7.4 billion, demonstrating the company's ability to achieve high growth efficiency despite its large scale, further solidifying its market position.
- Growth Potential for Twist: Twist Bioscience's revenue rose 19% to $110.7 million in Q2 of fiscal 2026, marking 13 consecutive quarters of growth; however, its net loss widened to $44 million, yet the partnership with Amazon provides significant momentum for future drug development.
- Market Outlook Analysis: Both companies showcase distinct approaches in AI-driven drug development, with Eli Lilly focusing on innovation in established drugs while Twist seeks higher-risk returns in synthetic DNA, reflecting the broad potential of AI in the pharmaceutical industry.
See More
Eli Lilly and Twist Bioscience: AI in Drug Development
- AI Innovation at Eli Lilly: Eli Lilly collaborates with OpenAI for drug discovery and establishes an AI co-innovation lab with Nvidia, aiming to accelerate drug development and enhance its position in the competitive pharmaceutical market.
- Strong Financial Performance: In Q1 2026, Eli Lilly reported a 56% revenue increase to $19.8 billion and a 168% surge in net income to $7.4 billion, indicating improved operational efficiency and promising future growth potential despite its large scale.
- Market Dynamics for Twist Bioscience: Twist Bioscience's revenue rose 19% to $110.7 million in Q2 2026, marking 13 consecutive quarters of growth, although net losses widened to $44 million, highlighting challenges faced during expansion.
- Partnership with Amazon: Twist Bioscience has become a key lab in Amazon's Bio Discovery platform, leveraging AI to design drugs and collaborate with real-world partners, which is expected to create new business growth opportunities and enhance its market competitiveness.
See More
Eli Lilly and Twist Bioscience's AI Drug Development Strategies
- AI Innovation at Eli Lilly: Eli Lilly collaborates with OpenAI for drug discovery and establishes an AI co-innovation lab with Nvidia to accelerate the identification of promising drug molecules, resulting in a 56% revenue increase to $19.8 billion and a 168% rise in net income to $7.4 billion in Q1 2026, indicating significant efficiency improvements.
- New Drug Potential: Lilly's newly approved weight-loss pill, Foundayo, which can be taken at any time, replaces injections and is expected to attract a broader patient base, further expanding market share and enhancing the company's position in the rapidly growing weight-loss drug market.
- Twist's Growth Risks: Twist Bioscience's stock has risen over 136% in the past year, despite a 26% decline over the past five years, with Q2 2026 revenue up 19% to $110.7 million, marking 13 consecutive quarters of revenue growth, although net loss widened to $44 million primarily due to a $7.2 million settlement.
- Partnership with Amazon: Twist's collaboration with Amazon positions it as a key lab in the Amazon Bio Discovery platform, leveraging AI to design drugs and develop them with real-world partners, highlighting the company's critical role in AI-driven drug development despite facing higher uncertainty.
See More
